Gland Pharma Shares Fall After ₹2,121 Cr Block Deal; Fosun Pharma Likely Seller

Gland Pharma Share Price: Gland Pharma shares traded with losses on Friday after 75 lakh shares, representing a 4.5% stake, changed hands through the block deal window. Based on the transaction value of ₹2,121 Cr, the shares were traded at an average price of around ₹2,828 apiece.

The identities of the official buyer and seller were not immediately known. However, Fosun Pharma is likely to be the seller after reports on Thursday indicated that the Chinese pharmaceutical major was looking to pare its stake in Gland Pharma. 

Gland Pharma shares were trading at ₹2,891.20 as of 10:15 am on September 4, down 0.57%. The stock has gained 68.48% so far in 2026 (year to date) and has risen 53.21% over the past year, from September 4, 2025 to September 4, 2026. 

As of 4th Sep, 10.33 AM

Why Did 4.5% Stake in Gland Pharma Change Hands?

The block deal involved 75 lakh Gland Pharma shares, equivalent to 4.5% of the company's equity. The transaction was valued at around ₹2,121 Cr, with an implied average price of approximately ₹2,828 per share.

Reports had earlier indicated that Fosun Pharma could sell up to a 5% stake through a block deal. The proposed transaction was initially pegged at ₹2,279.5 Cr, with a floor price of ₹2,763 per share, representing a 5% discount to Gland Pharma's Thursday closing price.

The reported transaction was also expected to carry a 12-month lock-up on any further share sale by the seller.

READ THIS ALSO: UltraTech Enters Wires & Cables With ₹1,800 Cr Ultravolt Investment

How Much Stake Does Fosun Pharma Hold in Gland Pharma?

Fosun Pharma Industrial held a 51.77% stake in Gland Pharma at the end of the June 2026 quarter, making it the company's largest shareholder.

If Fosun Pharma was the seller and the entire 4.5% transaction represented its stake sale, its holding would fall to around 47.3%. Public shareholders held the remaining 48.23% stake as of the June quarter.

How Did Gland Pharma Perform in Q1 FY27?

• Gland Pharma reported a 47.1% year-on-year increase in net profit to ₹317 Cr in the first quarter, compared with ₹215 Cr a year earlier.

• Revenue increased 19.6% to ₹1,800.2 Cr from ₹1,505.6 Cr, while EBITDA rose 33.1% to ₹489.2 Cr from ₹367.6 Cr.

• EBITDA margin also expanded to 27.2% from 24.4%.

• Separately, the USFDA concluded its routine GMP inspection at Gland Pharma's VSEZ sterile oncology formulations and API facilities with zero Form 483 observations.

Conclusion: What Does This Mean for Investors?

The ₹2,121 Cr block deal involving 4.5% of Gland Pharma has put the stock under pressure, with Fosun Pharma likely to be the seller. Investors will watch the promoter's revised holding and any further stake-sale activity, while the company's strong Q1 FY27 earnings and recent USFDA inspection outcome remain key developments.